New drugs benefit American patients. Increasing the number of drugs in the pipeline will likely boost drug spending but also increase the number of new or improved drug therapies. It will also increase the number of generic drugs 20 years down the road. Shortening the length of time it takes new drugs to gain approval would also boost competition with earlier drugs that are still under patent protection.
Category: Authors
Wednesday Links
- At 6 percent of GDP, the deficit of $1.8 trillion is unlike anything we’ve seen during times of relative prosperity.
- Krugman: the food stamp program is most important to overwhelmingly white rural counties that strongly supported Trump.
- Was there really a Our Lady of Fatima miracle in 1917?
- The Pharmaceutical Derangement Syndrome (PDS) explained.
- 14 reasons to like the big beautiful tax bill.
The Cost of Pet Cancer Care Rivals a Car, Yet Texas Limits Competition
This topic became an issue for me because of my dog Clementine. I recently wrote about her experience at the veterinarian. She had surgery for bladder stones, but the surgery did not resolve her problems. We took her back twice more, finally getting a referral to a specialist. A veterinary internal medicine specialist did a very thorough examination costing nearly $1,500. The pathology report found cancer that had metastasized.
Monday Links
- Against killing drug smugglers on speed boats. (NYT)
- FREOPP: To end the government shutdown, let heath plans age rate their premiums and create reinsurance. (WaPo)
- Study: The poorest Americans die, on average, nine years earlier than the wealthiest Americans.
- Premiums on healthcare.gov set to rise by 30%: “Without the expiring subsidies, healthy people will drop out.”
- Is the feminization of society the reason for the rise of wokeness?